KALA BIO, Inc. (KALA)

Market Cap	10.88M
Revenue (ttm)	n/a
Net Income (ttm)	-37.23M
Shares Out	7.02M
EPS (ttm)	-6.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	425,026
Open	1.600
Previous Close	1.570
Day's Range	1.510 - 1.600
52-Week Range	1.100 - 20.600
Beta	-2.11
Analysts	Buy
Price Target	31.50 (+1,932.26%)
Earnings Date	Nov 11, 2025

About KALA

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 20, 2017
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: KALA
• Website: https://www.kalarx.com

Analyst Summary

According to 3 analysts, the average rating for KALA stock is "Buy." The 12-month stock price target is $31.5, which is an increase of 1,932.26% from the latest price.

Price Target

$31.5

(1,932.26% upside)

Analyst Consensus: Buy